个人简介：

Dr. An is the founder of Curegenix. He is an expert in WNT signaling research with more than 20 years of drug discovery experiences in pharmaceutical industry. Prior to founding Curegenix, he was a Principlal Scientist / Project Leader at Amgen and a program director at Tularik in the US. He obtained an MD degree from Peking University Medical School and a PhD degree in Molecular Biology / Biochemistry from the University of Missouri-Columbia. After postdoctoral training in immunology at the University of California, San Francisco (UCSF), Dr. An became an assistant professor in the Department of Medicine at UCSF.

公司简介：

应用国际先进技术，研发全球首创First-in-class抗肿瘤、抗纤维化新药 。广州开发区科技领军人才，广州市创业领军人才，国家十二五重大新药创制专项，著名风险投资机构及跨国药厂支持 。磷酸源生萘啶CGX1321完成中美双报，开展国际多中心临床试验，在全球十多家顶级临床中心完成临床2a期试验（Harvard, Johns Hopkins, Duke, 北京肿瘤医院等) 。临床试验结果在美国临床肿瘤学会 (ASCO) 2023年会上应邀做口头报告 。自主研发项目聚焦WNT通路抑制剂，不涉猎其它靶点。将借助研发平台和丰富经验，为业内同仁提供临床前研究服务、中美临床试验咨询。